Optimizing pharma R&D workflows begins with connecting data, teams and the organization

The pharmaceutical industry faces immense pressure to accelerate innovation, mitigate development risks and maximize research and development (R&D) returns at scale. While advanced technologies like artificial intelligence (AI) and automation offer powerful solutions, fragmented tools, disconnected environments, siloed data and legacy R&D stacks complicate R&D workflows and hinder innovation.

The full potential of AI and automation technologies is, therefore, not realized.

To be sustainable in the long run, organizations must rethink their current research infrastructure. This includes everyone from the individual scientist all the way to the broader enterprise.

Why scattered scientific data is hurting progress

The core challenge is no longer generating insight; it’s translating insight into reproducible, scalable impact. However, scientific data remains scattered across instruments, applications and teams, and critical information like experimental intent, material lineage and decision rationale is rarely captured structurally as projects progress. Instead of accelerating discovery, fragmented data has become a hidden drag. Tools proliferate without coordination, data becomes increasingly difficult to trust or reuse and workflows fracture across organizational and technical boundaries.

Scientists spend more time navigating infrastructure than advancing research. Without structured scientific workflows and lifecycle continuity:

• AI operates in incomplete context and underperforms as an investment
• Automation remains fragile as manual scientific workflows lead to slower research and development cycles, higher experimental burden and missed opportunities
• Innovation struggles to move beyond the lab

What holds organizations back is the absence of a connected foundation that unites scientific reasoning with coordinated development and production. This fragmentation means knowledge is lost at critical handoffs, scale-up becomes reactive and downstream teams must often reconstruct earlier findings.

Dotmatics, which is now part of Siemens, provides a unifying R&D platform designed to connect diverse tools, data and teams, empowering faster innovation by:

• Enabling cross-domain collaboration
• Governing data handling
• Applying automation and AI to structured data

Luma unifies research systems and data to accelerate innovative outcomes in drug discovery and development.

Why legacy systems are incapable of keeping up with modern science

Scientific discovery has evolved dramatically, especially in areas like novel biologics and conjugates. However, the infrastructure supporting it hasn’t kept pace. The tools, data and workflows needed to innovate have outpaced the infrastructure that supports them as many R&D organizations still operate on systems designed for a far simpler era. 

As scientific ambition grows, the gap between what researchers need and what legacy environments can support widens, creating friction at every stage of innovation. 

Most organizations feel this strain in three critical ways:

Fragmented technology ecosystems slow scientific progress

Over time, R&D organizations accumulate hundreds of applications, each solving a narrow problem that is tied to a specific domain or function. While these tools may work well in isolation, they rarely work well together. Limited interoperability and inconsistent standards force scientists to jump between systems for experiment tracking, data analysis, visualization and reporting. The result is cognitive overload, manual workarounds and delayed insights, all of which undermine collaboration and productivity.

Siloed and inaccessible data breaks the scientific feedback loop

Fragmented tools inevitably lead to fragmented data. When information is scattered across vendors, formats and repositories, scientists must rely on manual, error-prone processes to collect, prepare, move and reuse data. Without consistent standards for structure, quality, governance and security, data loses its value, insights are missed, reproducibility suffers and the promises of advanced analytics and AI remain out of reach.

Complex enterprise architecture limits innovation

Modern R&D requires platforms that can span disciplines, adapt to new science and support enterprise‑wide decision making. Legacy architectures struggle to deliver this cohesion, custom-built integrations are expensive and difficult to maintain and narrowly-focused off‑the‑shelf solutions fail to support cross‑domain workflows. These constraints make it difficult to scale innovation, leverage AI or generate meaningful enterprise insights.

Luma is different. The enterprise R&D platform connects multi-domain science, data and decision making, helping R&D teams work more efficiently and innovate like never before.

One platform built for scientists, teams and the entire enterprise 

Optimizing modern R&D is no longer about improving isolated workflows or speeding up individual steps. Breakthroughs increasingly depend on collaboration across disciplines, seamless handoffs between teams and the ability to connect data and technologies across multi‑stage, multi‑domain processes. To support this reality, especially in AI‑aided R&D, a solution must strike a careful balance: empower individual scientists while providing a unified foundation that is essential for cross-domain workflows and dataflows.

The AI‑native Luma data management and workflow automation platform connects people, data and technology in a single, unified environment. The result is an R&D ecosystem where enterprise data is harmonized, workflows span domains without friction and teams can collaborate more effectively.

This unified multimodal context transforms fragmented scientific work into a structured, connected foundation for scalable innovation, supporting individual scientists, cross‑domain teams and the broader organization on a single foundation. This enables scientific work to scale without sacrificing usability or rigor.

This approach streamlines cross‑domain workflows, reduces reliance on manual data handling and eliminates brittle custom integrations. By capturing and modeling relationships across entities, samples, assays and instruments within a single contextual framework, organizations can preserve scientific intent and continuity from discovery through development.

Enabling the strategic use of automation, modeling and AI

Luma modernizes R&D architecture to support:

• Automation
• Advanced analytics
• Modeling
• Simulation
• AI

The platform governs and automates data across complex workflows, normalizing and structuring multimodal data from internal systems as well as third-party instruments, equipment, software and databases. It can adapt to workflow variability and user preferences, delivering personalized, scalable scientific intelligence that accelerates discovery across the enterprise and pushes science forward.

This structured scientific foundation makes AI meaningful and scalable, ensuring that AI investments deliver on their promise.

The realized impact of improving R&D efficiency

With Luma, R&D organizations can fundamentally reshape the discovery funnel by modernizing their research and data processes. Digital transformation moves beyond incremental productivity gains, replacing fragmented research and data processes with a connected, intelligent foundation that accelerates progress from early discovery through development.

Scientists gain trusted cross-modal reasoning, reproducibility and automation-ready workflows, while leaders gain confidence that knowledge won’t be lost at critical handoffs.

Luma drives efficiencies at every step, letting experts:

• Leverage automation and AI to uncover promising candidates faster
• Identify failures earlier
• Develop safe, effective and high-potential candidates
• Minimize time wasted on candidates with a low probability of success

This shift reduces costly late-stage failures and sharpens organizational focus on the most viable, high-impact opportunities. The result is a smarter, faster R&D engine that brings safer, more effective and higher-value products to market in less time. 

Luma provides confidence that research and discovery efforts are optimized for speed, accuracy and innovation, empowering pharmaceutical companies to remain at the forefront of scientific discovery. By adopting a unified therapeutic candidate research and design solution, pharmaceutical companies gain unparalleled clarity and control over their R&D processes.

Stay up to date on pharmaceutical insights

FAQs about R&D workflows in pharma

1. What are the main challenges pharmaceutical R&D organizations face today?

Pharmaceutical R&D organizations are under pressure to innovate faster, reduce risks and maximize returns. They often struggle with fragmented tools and disconnected environments, siloed data and complex legacy R&D systems. This leads to challenges such as scientists spending too much time on infrastructure navigation, AI operating with incomplete context, fragile automation and innovation struggling to move beyond the lab.

2. Why are legacy R&D systems no longer sufficient for modern scientific discovery?

Modern scientific discovery, especially in areas like novel biologics and conjugates, has outpaced the capabilities of legacy R&D systems. These older systems often lead to fragmented technology ecosystems with hundreds of applications that don’t work well together, siloed and inaccessible data that hinders advanced analytics and complex enterprise architectures that limit innovation and scalability.

3. What are the key benefits of implementing a unified R&D platform

A unified R&D platform helps organizations modernize their research and data processes, moving beyond incremental productivity gains. It provides a connected, intelligent foundation that accelerates progress from early discovery through development. This results in trusted cross-modal reasoning, reproducible and automation-ready workflows, and the ability to bring safer, more effective and higher-value products to market faster.